Literature DB >> 18692506

Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.

Steve Bryson1, Jean-Philippe Julien, David E Isenman, Renate Kunert, Hermann Katinger, Emil F Pai.   

Abstract

The monoclonal antibody 2F5 neutralizes a broad range of human immunodeficiency virus-1 isolates via a conserved epitope on the viral glycoprotein gp41. The conformation of the principal epitope is a type I beta-turn centered on gp41 residues (664)DKW(666); in addition, binding studies indicate that residues N- and C-terminal to this core as well as structurally more distant parts of gp41 also contribute to the interaction. Ab2/3H6 is an anti-idiotypic antibody that inhibits the interaction between 2F5 and gp41 and as such, Ab2/3H6 may, in principle, possess a paratope that mimics the gp41 epitope. To establish the potential of Ab2/3H6 to serve as a guide for the design of vaccine components against human immunodeficiency virus, we investigated the crystal structure of the heterodimeric complex of Ab2/3H6 F(ab) and 2F5 F(ab)'. Ab2/3H6 F(ab) binds to 2F5 F(ab)' via a helix-like protrusion formed by residues (58(H))RYSPSLNTRL(67(H)) of the 2F5 F(ab)' variable domain and proximal to but not overlapping with the gp41 (664)DKW(666) epitope-binding pocket. This defines Ab2/3H6 as an anti-idiotypic antibody of the Ab2gamma class, i.e., an antigen-inhibitable idiotype that does not carry the internal image of the linear primary gp41 (662)ELDKWAS(668) epitope.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692506     DOI: 10.1016/j.jmb.2008.07.057

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  11 in total

1.  Structural Mimicry of the Dengue Virus Envelope Glycoprotein Revealed by the Crystallographic Study of an Idiotype-Anti-idiotype Fab Complex.

Authors:  Yee Hwa Wong; Boon Chong Goh; She Yah Lim; En Wei Teo; Angeline P C Lim; Pete C Dedon; Brendon J Hanson; Paul A MacAry; Julien Lescar
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

2.  Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery.

Authors:  Michael Mühle; Kerstin Hoffmann; Martin Löchelt; Joachim Denner
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

3.  Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].

Authors:  Mauro Lapelosa; Gail Ferstandig Arnold; Emilio Gallicchio; Eddy Arnold; Ronald M Levy
Journal:  J Mol Biol       Date:  2010-02-04       Impact factor: 5.469

4.  Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1.

Authors:  Johannes S Gach; Paul G Furtmüller; Heribert Quendler; Paul Messner; Ralf Wagner; Hermann Katinger; Renate Kunert
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

5.  Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.

Authors:  Steve Bryson; Jean-Philippe Julien; Rosemary C Hynes; Emil F Pai
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

6.  Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost study.

Authors:  Alexander Mader; Renate Kunert
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

Review 7.  The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.

Authors:  Huan Liu; Xiaojie Su; Lulu Si; Lu Lu; Shibo Jiang
Journal:  Protein Cell       Date:  2018-04-17       Impact factor: 14.870

8.  Structural basis for the recognition in an idiotype-anti-idiotype antibody complex related to celiac disease.

Authors:  Anna Vangone; Safwat Abdel-Azeim; Ivana Caputo; Daniele Sblattero; Roberto Di Niro; Luigi Cavallo; Romina Oliva
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

9.  Antibody humanization by molecular dynamics simulations-in-silico guided selection of critical backmutations.

Authors:  Christian Margreitter; Patrick Mayrhofer; Renate Kunert; Chris Oostenbrink
Journal:  J Mol Recognit       Date:  2016-01-08       Impact factor: 2.137

10.  Lessons learned from merging wet lab experiments with molecular simulation to improve mAb humanization.

Authors:  L Schwaigerlehner; M Pechlaner; P Mayrhofer; C Oostenbrink; R Kunert
Journal:  Protein Eng Des Sel       Date:  2018-07-01       Impact factor: 1.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.